Professor Anthony Keech

Professor
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 2 9562 5000 OR 5004
Fax +61 2 9562 5090

Website Related website

Map

Biographical details

Anthony Keech is a Professor of Medicine, Cardiology and Epidemiology, in the Department of Medicine at the University of Sydney and a practising Consultant Cardiologist at the Royal Prince Alfred Hospital in Sydney. He holds an NHMRC Principal Research Fellowship and is deputy director of the NHMRC Clinical Trials Centre.

He is a leading international investigator in cardiovascular trials particularly recognised for his work in lipids and heart disease, and has been a lead investigator in the Heart Protection Study, the LIPID Trial and the FIELD Trial. He is also internationally recognised for his collaborative research involving treatment strategies for acute coronary syndromes, risk factor reduction in coronary heart disease and the non-invasive prediction of vascular disease. Tony has over 106 peer-reviewed publications and over 240 papers, letters and refereed conference papers in total, including numerous peer-reviewed publications in the leading journals in research areas of cardiovascular disease, dyslipidemia and diabetes, and their prevention and treatment: The Lancet (18), Circulation (9), New England Journal of Medicine (3), European Heart Journal (10), Diabetes Care (2), Diabetic Medicine (2) with a high impact on clinical practice and health policy. Tony has been a chief investigator on over $152M of competitive research grants, including several of the largest grants ever awarded to Australian investigators. He serves on the editorial boards of 3 international Journals, including as the Clinical Trials Editor for one, and reviews many manuscripts for these and other international journals each year. He has jointly lead a team of 140 staff at the NHMRC Clinical Trials Centre including 19 academics, 10 other post-doctoral staff and around 60 other research staff and together with the Director, oversees all aspects of the Centre’s functions. He also chairs the CTC Research Committee which determines the CTCs overall research priorities. His international recognition in medical research is also manifest by invitations to present at many international meetings including 18 international plenary lectures, 28 invited lectures at numerous other international meetings over the past 5 years. He is a member of 10 international policy groups and research committees. He has also made significant contributions to University teaching (leading the curriculum development and delivery in controlled trials teaching for the MPH and M Clin Epi degrees) and taking a lead role in short courses in clinical trials and clinical research methods throughout Australia and the Asia-Pacific region. He undertakes supervision of students for PhD and MPH degrees and is a member of the University’s Postgraduate Committee of the College of Health Sciences. He serves on many national and international committees including the Ethics Committee Trials Subcommittee of RPAH, the NSW Shared Scientific Assessment Committee for multi-centre clinical research in NSW, founding member and current treasurer of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases and Chairman of the Clinical Trials Working Group of the ANZ Cardiac Society.

Research interests

Professor Anthony Keech is Deputy Director of the NHMRC Clinical Trials Centre. He is a NHMRC Principal Research Fellowship. He is also a practising Consultant Cardiologist at the Royal Prince Alfred Hospital. His teaching interests relate to general aspects of epidemiology, prevention and treatment of vascular diseases, together with research methods for epidemiological and randomised trials research. In addition, to the training of medical registrars and advanced trainees is on going.

His research interest focus on the rigorous conduct of randomised controlled trials and epidemiological studies, addressing problems of national and international importance - treatments of acute myocardial infarction (heart attack) and acute coronary syndromes (unstable angina), coronary heart disease prevention in relation to dyslipidaemia and diabetes particularly, and combining evidence using prospective meta-analysis.

Selected grants

2014

  • Purchase of the Retina Tomograph Platform with Corneal Confocal Microscope module; Keech A, Jenkins A; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Advancing the evidence base for care and policy in priority health areas; Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner C; National Health and Medical Research Council (NHMRC)/Program Grants.
  • FIELD LIFE Study: Unlocking gene - environment interactions in Type 2 diabetes and its complications; Keech A, Hardikar A, Jenkins A, Blankenberg S, Best J; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Cobas Integra 400+ Biochemical Analyzer; Keech A; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Peripheral vascular disease in type 2 diabetes; Keech A; Royal Australasian College of Physicians/Scholarship.
  • A calculator for personalised HbA1c targets for individuals with type 2 diabetes; Colagiuri S, Keech A; Australian Diabetes Society/ADS-Servier National Action Plan Grants in Memory of Barry Young.
  • Senior Principal Research Fellowship; Keech A; National Health and Medical Research Council (NHMRC)/Career Awards: Research Fellowships.

2011

  • Reducing Impulsive Behaviour in Repeat Violent Offenders Using a Selective Serotonin Reuptake Inhibitor (Zoloft); Gebski V, Keech A, Chappell D; National Health and Medical Research Council (NHMRC)/Partnership Projects.
  • China-Australia Collaborations in Diabetes and Obesity Research; Keech A; DVC International/IPDF Grant.

2010

  • Unlocking genetic factors predicting type 2 diabetes complications for clinical practice: The Field Study; Keech A, Best J, Jenkins A, Sullivan D, Twigg S; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Evaluating whether eye blood vessel changes predict heart disease in people with deabetes.; Keech A, Mitchell P; Heart Foundation of Australia/Grants-in-Aid.

2008

  • Clinical trials advances for better health outcomes; Simes R, Keech A, Gebski V, Stockler M; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • NHMRC - Research Fellowship; Keech A; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.
  • Biomarkers and genetic determinants of cardiovascular risk in diabetes: the FIELD study; Keech A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • FIELD Biomarker studies; Keech A; Laboratories Fournier (France)/Research Support.

2006

  • FIELD substudies, research and analysis.; Keech A, Simes R; Laboratoires Fournier/Research grant.
  • TBA: Roche Diagnostics; Hughes C, Gebski V, Keech A, Dignan R; Roche Products Pty Limited/Research Grant.
  • Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository; Simes R, Keech A, Gebski V, Hague W, Stockler M; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2005

  • LIPID and LIPID Cohort Studies (BMS); Simes R, Hague W, Keech A; Bristol Myers Squibb/Research Grant.
  • Assessment and research related services on medical technologies and procedures to MSAC.; Keech A; Commonwealth Department of Health and Ageing/Research and Development.

2003

  • 4 x Ultra-low temperature freezers with racks and auto dial alarm system; Keech A; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Advances in clinical trials research and evidence-based decision making; Marschner C, Stockler M, Keech A, Simes R, Gebski V; National Health and Medical Research Council (NHMRC)/Program Grants.

2002

  • Clinical medical and science research; Keech A; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.
  • NHMRC Clinical Trials Centre; Simes R, Keech A; National Health and Medical Research Council (NHMRC)/Centre of Clinical Research Excellence.
  • Research Fellowship; Keech A; University of Sydney/Research & Development.

2000

  • Asian audit study; Keech A; Merck Sharpe and Dohme Australia Pty Ltd/MSD Research Foundation.
  • Provision of assessment and research related services on medical technologies and procedures for the Medical Services Advisory Committee (MSAC); Simes R, Eckermann S, Keech A, Irwig L, Ghersi D, Stockler M, Gebski V, Eckermann S, Lord S, Howard K, Salkeld G; Department of Health and Ageing (Federal)/Research Support.
  • Symphony; Keech A, Simes R; The Cleveland Clinic Foundation/Contract Research.
  • Vascular reactivity substudy; Celermajer D, Keech A; FIELD/Not Known.
  • Field study: Clinical trial of drugs; Keech A; Laboratories Fournier (France)/Research Support.
  • The HERO-2 study.; Simes R, Keech A; The Medicines Company (USA)/Project Grant.
  • TBA: Merck Asia; Ritchie G, Keech A; Merck Asia/Project Grant.
  • Heart Protection Study (UK Med Research Council); Collins R, Keech A, Peto R P, Sleight P; UK Medical Research Council (MRC UK)/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Edited Books

  • Keech, A., Gebski, V., Pike, R. (2007). Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: AMPCo.

Book Chapters

  • Donaghue, K., Keech, A., Craig, M., O'Connell, P. (2012). A 'cure' for diabetes and its complications. In Louise A. Baur, Stephen M. Twigg, Roger S.Magnusson (Eds.), A Modern Epidemic: Expert Perspectives on Obesity and Diabetes, (pp. 401-420). Sydney, Australia: Sydney University Press.
  • Cook, D., Keech, A., Gebski, V., Pike, R., Wonders, S. (2008). Balancing the outcomes: reporting harms (adverse events). In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 132-142). Sydney: AMPCo.
  • Keech, A., Gebski, V., Forder, P. (2007). Allocation concealment and blinding: when ignorance is bliss. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 54-64). Sydney: AMPCo.
  • Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
  • Keech, A., Gebski, V., Burgess, D. (2007). Baseline data in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 86-91). Sydney: AMPCo.
  • Keech, A., Gebski, V., Kirby, A. (2007). Determining the sample size in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 28-38). Sydney: AMPCo.
  • Keech, A., Gebski, V., Vachan, B. (2007). Flow of participants in randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 72-78). Sydney: AMPCo.
  • Keech, A., Seale, J., Gebski, V. (2007). Generalising the results of trials to clinical practice. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 149-153). Sydney: AMPCo.
  • Keech, A., Gebski, V., Heritier, S. (2007). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 92-98). Sydney: AMPCo.
  • Keech, A., Gebski, V., Pike, R., Granger, R. (2007). Interpreting the results of a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 143-148). Sydney: AMPCo.
  • Keech, A., Ghersi, D., Gebski, V., Pike, R. (2007). Introducing the report of a randomised controlled trial: the title, abstract, scientific background and rationale. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 8-10). Sydney: AMPCo.
  • O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Managing the resource demand of a large sample in clinical trials: can you succeed with fewer subjects? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 39-45). Sydney: AMPCo.
  • Keech, A., Gebski, V., Lord, S. (2007). Multiple analyses in clinical trials: sound science or data dredging? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 123-131). Sydney: AMPCo.
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 154-161). Sydney: AMPCo.
  • Beller, E., Gebski, V., Keech, A. (2007). Randomisation in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 46-53). Sydney: AMPCo.
  • Gebski, V., Beller, E., Keech, A., Van Der Weyden, M. (2007). Randomised Controlled Trials: Elements of a Good Study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 7-22). Sydney: AMPCo.
  • Keech, A., Gebski, V., Beller, E., Van Der Weyden, M. (2007). Randomised controlled trials: elements of a good study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 1-7). Sydney: AMPCo.
  • Hague, W., Keech, A., Gebski, V., Pike, R. (2007). Recruitment to randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 78-85). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Selecting participants for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 11-15). Sydney: AMPCo.
  • Brighton, J., Gebski, V., Keech, A. (2007). Specifying intervention in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 16-20). Sydney: AMPCo.
  • Keech, A., Gebski, V., Marschner, C. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 21-26). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Statistical methods in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 65-71). Sydney: AMPCo.
  • Cook, D., Keech, A., Gebski, V. (2007). Subgroup analysis in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 105-113). Sydney: AMPCo.

Journals

  • White, H., Tonkin, A., Simes, R., Stewart, R., Mann, K., Thompson, P., Colquhoun, D., West, M., Nestel, P., Sullivan, D., Keech, A., et al (2014). Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina. Journal of the American College of Cardiology, 63(4), 345-354. [More Information]
  • Sullivan, T., Duque, G., Keech, A., Herrmann, M. (2013). An Old Friend in a New Light: The Role of Osteocalcin in Energy Metabolism. Cardiovascular Therapeutics (Online), 31(2), 65-75. [More Information]
  • Noonan, J., Jenkins, A., Ma, J., Keech, A., Wang, J., Lamoureux, E. (2013). An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, 62(12), 3968-3975. [More Information]
  • Ghosh, J., Martin, A., Keech, A., Chan, K., Gomes, S., Singarayar, S., McGuire, M. (2013). Balloon Warming Time Is the Strongest Predictor Of Late Pulmonary Vein Electrical Reconnection Following Balloon Cryoablation for Atrial Fibrillation. Heart Rhythm, 10(9), 1311-1317. [More Information]
  • White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, C., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
  • Ting, R., Keech, A. (2013). Fenofibrate and renal disease: Clinical effects in diabetes. Clinical Lipidology, 8(6), 669-680. [More Information]
  • Simo, R., Roy, S., Behar-Cohen, F., Keech, A., Mitchell, P., Wong, T. (2013). Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Current Medicinal Chemistry, 20(26), 3258-3266. [More Information]
  • Olver, I., Keech, A. (2013). Forming networks for research: proposal for an Australian clinical trials alliance. Medical Journal of Australia, 198(5), 254-255. [More Information]
  • Dignan, R., Keech, A., Gebski, V., Mann, K., Hughes, C. (2013). Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. International Journal of Cardiology, 168(6), 5378-5384. [More Information]
  • Chan, K., O'Connell, R., Sullivan, D., Hoffmann, L., Rajamani, K., Whiting, M., Donoghoe, M., Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng, M., Keech, A. (2013). Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia: clinical and experimental diabetes and metabolism, 56(4), 724-736. [More Information]
  • Hankey, G., Anderson, N., Ting, R., Veillard, A., Romo, M., Wosik, M., Sullivan, D., O'Connell, R., Hunt, D., Keech, A. (2013). Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. Journal of Neurology, Neurosurgery and Psychiatry, 84(3), 281-287. [More Information]
  • Chen, Y., Hu, Y., Lin, M., Jenkins, A., Keech, A., Mott, R., Lyons, T., Ma, J. (2013). Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes, 62(1), 261-272. [More Information]
  • Ting, R., Keech, A., Drury, P., Donoghoe, M., Hedley, J., Jenkins, A., Davis, T., Lehto, S., Celermajer, D., Simes, R., Rajamani, K., et al (2012). Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment - The FIELD Study. Diabetes Care, 35(2), 218-225. [More Information]
  • Tonkin, A., Hunt, D., Voysey, M., Kesaniemi, Y., Hamer, A., Waites, J., Mahar, L., Mann, S., Glasziou, P., Forder, P., Simes, R., Keech, A. (2012). Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal, 163(3), 508-514. [More Information]
  • Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V. (2012). Effects of Fibrates in Kidney Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 60(20), 2061-2071. [More Information]
  • Best, J., Drury, P., Davis, T., Taskinen, M., Kesaniemi, Y., Scott, R., Pardy, C., Voysey, M., Keech, A. (2012). Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort. Diabetes Care, 35(5), 1165-1170. [More Information]
  • Emberson, J., Kearney, P., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., Collins, R., Simes, R., et al (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175 000 people in 27 randomised trials of statin therapy. PLoS One, 7(1), 1-10. [More Information]
  • Preiss, D., Tikkanen, M., Welsh, P., Ford, I., Lovato, L., Elam, M., laRosa, J., DeMicco, D., Colhoun, H., Goldenberg, I., Keech, A., et al (2012). Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis. JAMA, 308(8), 804-811. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Herrmann, M., Whiting, M., Veillard, A., Ehnholm, C., Sullivan, D., Keech, A. (2012). Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study. Clinical Chemistry and Laboratory Medicine, 50(12), 2213-2219. [More Information]
  • Fulcher, J., Keech, A. (2012). The case for more intensive use of statins. Therapeutic Advances in Chronic Diseases, 3(5), 201-210. [More Information]
  • Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, R., Barnes, E., Voysey, M., Gray, A., Collins, R., Baigent, C., et al (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. [More Information]
  • Ng, M., Yong, A., Ho, M., Shah, M., Chawantanpipat, C., O'Connell, R., Keech, A., Kritharides, L., Fearon, W. (2012). The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Circulation. Cardiovascular Interventions, 5(4), 515-522. [More Information]
  • Keech, A., Simes, R., Fulcher, J. (2012). The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 197(3), 130-131. [More Information]
  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P., Neil, G., Haapamäki, H., Keech, A. (2011). Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 94(2), 284-290. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290. [More Information]
  • Drury, P., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., Fassett, R., Ansquer, J., Dixon, P., Davis, T., Pardy, C., Keech, A., et al (2011). Estimated Glomerular Filtration Rate and Albuminuria are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(1), 32-43. [More Information]
  • Scott, R., Donoghoe, M., Watts, G., O'Brien, R., Pardy, C., Taskinen, M., Davis, T., Colman, P., Manning, P., Fulcher, G., Keech, A. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), 102-1-102-8. [More Information]
  • Hayes, A., Clarke, P., Voysey, M., Keech, A. (2011). Simulation of Quality-Adjusted Survival in Chronic Diseases: An Application in Type 2 Diabetes. Medical Decision Making: an international journal, 31(4), 559-570. [More Information]
  • Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One, 5(1), e8580-1-e8580-10. [More Information]
  • Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Mann, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia: clinical and experimental diabetes and metabolism, 53(9), 1846-1855. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290. [More Information]
  • Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., Keech, A., Simes, R., et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. [More Information]
  • Burgess, D., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T., Laakso, M., Kesaniemi, Y., Zhang, J., Sy, R., Keech, A., et al (2010). Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal, 31(1), 92-99. [More Information]
  • Chan, K., Chawantanpipat, C., Gattorna, T., Chantadansuwan, T., Kirby, A., Madden, A., Keech, A., Ng, M. (2010). The relationship between coronary stenosis severity and compression type coronary artery movement in acute myocardial infarction. American Heart Journal, 159(4), 584-592. [More Information]
  • Keech, A., Horowitz, J. (2009). Cost-effectiveness Considerations of Cardiovascular Therapeutics. Heart, Lung and Circulation, 18(2), 118-122. [More Information]
  • Rajamani, K., Coleman, P., Li, L., Best, J., Voysey, M., D'Emden, M., Laakso, M., Baker, J., Keech, A., FIELD study investigators, F. (2009). Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet, 373(9677), 1780-1788. [More Information]
  • Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Boey (Tse), D., Taskinen, M., Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 32(3), 493-498. [More Information]
  • Soderberg, S., Colquhoun, D., Keech, A., Yallop, J., Barnes, E., Pollicino, C., Simes, R., Tonkin, A., Nestel, P. (2009). Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity, 33(1), 123-130. [More Information]
  • Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
  • Clarke, P., Hayes, A., Glasziou, P., Scott, R., Simes, R., Keech, A. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61-68. [More Information]
  • Hayes, A., Clarke, P., Glasziou, P., Simes, R., Drury, P., Keech, A. (2008). Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care, 31(4), 795-797. [More Information]
  • Kearney, P., Blackwell, L., Collins, R., Keech, A., Simes, R., Peto, R., Armitage, J., Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet, 371, 117-125. [More Information]
  • Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - author's reply. The Lancet, 371, 722.
  • Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - Authors' reply. The Lancet, 371(9614), 722-722.
  • Keech, A., Mitchell, P. (2008). FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy. Review of Endocrinology.
  • Hiukka, A., Westerbacka, J., Leinonen, E., Watanabe, H., Wiklund, O., Hulten, L., Salonen, J., Tuomainen, T., Yki-Järvinen, H., Keech, A., et al (2008). Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. Journal of the American College of Cardiology, 52(25), 2190-2197. [More Information]
  • Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry (Washington, DC), 54(6), 1038-1045. [More Information]
  • Kearney, P., Keech, A., Simes, R., Collins, R. (2008). Statins and diabetes: authors' reply. The Lancet, 371(9626), 1752-1752.
  • Scott, R., D'Emden, M., Best, J., Drury, P., Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D., Barter, P., Taskinen, M., Copt, S., Keech, A., et al (2007). Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate. Circulation, 116, II_838.
  • Marschner, C., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
  • Davis, W., Davis, T., Keech, A. (2007). Calculating cardiovascular risk in people with diabetes. Diabetes Management Journal, 18(March), 32-32.
  • Banks, E., Redman, S., Jorm, L., Armstrong, B., Bauman, A., Beard, J., Bowles, H., Butow, P., Cardona-Morrell, M., Clarke, J., Cowie, C., Cumming, R., Fragar, L., Keech, A., Kendig, H., Kricker, A., Morgan, G., Nutbeam, D., Quine, S., Salkeld, G., et al (2007). Cohort Profile the 45 and Up Study. International Journal of Epidemiology, September 2007, 1-6.
  • Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
  • Keech, A., Pike, R., Granger, R., Gebski, V. (2007). Interpreting the results of a clinical trial. Medical Journal of Australia, 186(9), 318-319. [More Information]
  • Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A., Taskinen, M. (2007). Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia: clinical and experimental diabetes and metabolism, 50(10), 2067-2075. [More Information]
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. Medical Journal of Australia, 186(7), 368-370. [More Information]
  • Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.
  • Keech, A., Simes, R. (2006). Clinical trial design & management: The role of PPAR-ALPHA agonists in prevention of CVD. Atherosclerosis Supplements, 7(3), 174-174.
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment - Reply. The Lancet, 367(9509), 470-471.
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment-authors' reply [letter]. The Lancet, 367(9509), 470-471.
  • Alexander, K., Newby, L., Bhapkar, M., White, H., Hochman, J., Pfisterer, M., Moliterno, D., Peterson, E., Van de Werf, F., Simes, R., Keech, A., et al (2006). International variation in invasive care of the elderly with acute coronary syndromes. European Heart Journal, 27(13), 1558-1564. [More Information]
  • Burgess, D., Kilborn, M., Keech, A. (2006). Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. European Heart Journal, 27(23), 2846-2857. [More Information]
  • Grieve, S., Ansquer, J., Keech, A. (2006). Micronized fenofibrate: A useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology, 2(6), 635-646.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. Journal of the National Cancer Institute, 98(17), 1021-1022.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. Journal of the National Cancer Institute, 98(1), 26-38. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding [reply]. Medical Journal of Australia, 183(3), 165-166.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding: when ignorance is bliss. Medical Journal of Australia, 182(2), 87-89. [More Information]
  • McAvoy, B., Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family Physician, 34(4), 297-298. [More Information]
  • Briffa, T., Eckermann, S., Griffiths, A., Harris, P., Heath, M., Freedman, B., Donaldson, L., Briffa, N., Keech, A. (2005). Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Medical Journal of Australia, 183(9), 450-455. [More Information]
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with chronic kidney disease and diabetes mellitus. Hypertension, 46(4), 900-901.
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology, 16(12), 3748-3754. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278. [More Information]
  • Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
  • Lundman, P., Keech, A., Griffiths, K., Pillai, A., Celermajer, D. (2005). New carotid plaque formation is very common in adult patients with Type 2 diabetes mellitus. Diabetic Medicine, 22(3), 355-356. [More Information]
  • Keech, A., Grieve, S., Patel, A., Griffiths, K., Skilton, M., Watts, G., Marwick, T., Groshens, M., Celermajer, D. (2005). Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. Diabetic Medicine, 22(11), 1558-1565. [More Information]
  • Keech, A., Wonders, S., Cook, D., Gebski, V. (2004). Balancing the outcomes: reporting adverse events. Medical Journal of Australia, 181(4), 215-218.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. The Lancet, 363(9411), 757-767.
  • Colquhoun, D., Keech, A., Hunt, D., Marschner, C., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
  • Seale, J., Gebski, V., Keech, A. (2004). Generalising the results of trials to clinical practice. Medical Journal of Australia, 181(10), 558-560.
  • O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.
  • Lord, S., Gebski, V., Keech, A. (2004). Multiple Analyses In Clinical Trials: Sound Science Or Data Dredging? Medical Journal of Australia, 181(8), 452-454.
  • Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
  • Cook, D., Gebski, V., Keech, A. (2004). Subgroup analysis in clinical trials. Medical Journal of Australia, 180(6), 289-291.
  • Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
  • Barter, P., Best, J., Colman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Glasziou, P., Hunt, D., Keech, A., Forder, P., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11.
  • Sniderman, A., Furberg, C., Keech, A., Roeters van Lennep, J., Frohlich, J., Jungner, I., Walldius, G. (2003). Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. The Lancet, 361(9359), 777-780.
  • Burgess, D., Gebski, V., Keech, A. (2003). Baseline data in clinical trials. Medical Journal of Australia, 11, 105-107.
  • Pike, R., Keech, A., Simes, R. (2003). Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Medical Journal of Australia, 178(7), 316-317.
  • Kirby, A., Gebski, V., Keech, A. (2003). Determining the sample size in a clinical trial [in reply]. Medical Journal of Australia, 178(7), 358-358.
  • Vachan, B., Gebski, V., Keech, A. (2003). Flow of participants in randomised studies. Medical Journal of Australia, 178, 347-349.
  • Heritier, S., Gebski, V., Keech, A. (2003). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Medical Journal of Australia, 11, 438-440.
  • Keech, A., Gebski, V. (2003). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects. Medical Journal of Australia, 178(7), 356-357.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., et al (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet, 361(9374), 2005-2016.
  • Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., McAvoy, B., Neale, M., Pollock, C., et al (2003). Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus, (21 July 2003), 1-14.
  • Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
  • Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721.
  • Gebski, V., Keech, A. (2003). Statistical methods in clinical trials. Medical Journal of Australia, 11, 182-184.
  • Kilian, J., Keech, A., Adams, M., Celermajer, D. (2002). Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. Coronary Artery Disease, 13(3), 155-159.
  • Sacks, F., Tonkin, A., Craven, T., Pfeffer, M., Shepherd, J., Keech, A., Furberg, C., Braunwald, E. (2002). Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105(12), 1424-1428.
  • Kirby, A., Gebski, V., Keech, A. (2002). Determining the sample size in a clinical trial. Medical Journal of Australia, , 256-257.
  • Neal, B., MacMahon, S., Ohkubo, T., Tonkin, A., Wilcken, D., Keech, A. (2002). Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. European Heart Journal, 23(19), 1509-1515.
  • Simes, R., Furberg, C., Braunwald, E., Davis, B., Ford, I., Tonkin, A., Shepherd, J., Keech, A. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. European Heart Journal, 23(3), 207-215.
  • Keech, A., Neal, B., MacMahon, S., Ohkubo, T., Brnabic, A., Tonkin, A. (2002). Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. Journal Of The Renin-Angiotensin-Aldosterone System, 3(4), 270-276.
  • Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387.
  • Keech, A., Gebski, V. (2002). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Medical Journal of Australia, 177(8), 437-439.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360, 23-33.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360(9326, 6 July 2002), 7-22.
  • Beller, E., Gebski, V., Keech, A. (2002). Randomisation in clinical trials. Medical Journal of Australia, 177(10), 565-567.
  • Simes, R., Keech, A., et, A. (2002). Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 105(3), 316-321.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • Richie, G., Keech, A., Yamamoto,, A., Nakamura, H., Hosoda,, S., Nobuyoshi,, M., Matsuzaki, M., Tan, C., Mabuchi, H., Horibe, H., et al (2002). Risk factors for coronary heart disease in the Japanese - Comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Journal of Atherosclerosis and Thrombosis, 9(4), 191-199.
  • Pfeffer, M., Keech, A., Sacks, F., Cobbe, S., Tonkin, A., Byington, R., Davis, B., Friedman, C., Braunwald, E. (2002). Safety and tolerability of pravastatin in long-term clinical trials. Circulation, 105(20), 2341-2346.
  • Brighton, J., Gebski, V., Keech, A. (2002). Specifying interventions in a clinical trial. Medical Journal of Australia, , 281-282.
  • Gebski, V., Marschner, C., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492.
  • Ritchie, G., Keech, A. (2001). Asia-Pacific collaboration on coronary heart disease risk factor intervention: study desing and methods. Heart, Lung and Circulation, 10, 24-29.
  • Hughes, C., Keech, A., Cox,, N. (2001). Myocardial infarction due to saphenous vein graft compression by an extracardiac mass. Heart, Lung and Circulation, 10, 35-37.
  • Gebski, V., Beller, E., Keech, A. (2001). Randomized controlled trails: elements of a good study. Medical Journal of Australia, 175, 272-274.
  • Ghersi, D., Gebski, V., Keech, A. (2001). Scientific background and rationale for a randomised controlled trial. Medical Journal of Australia, 175(7), 386-386.
  • Keech, A., Gebski, V. (2001). Selecting participants for clinical trials. Medical Journal of Australia, 175(9), 490-491.
  • Miller, O., Tang, S., Keech, A., Pigott, N., Beller, E., Celermajer, D. (2000). Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. The Lancet, 356(9240), 1464-1469.

Conferences

  • Keech, A. (2006). Challenges in undertaking primary prevention trials. 54th Annual Scientific Meeting of the Cardiac Society of Australian and New Zealand.
  • Keech, A. (2006). Effects of long-term fenofibrate therapy in the FIELD study. Meeting of the Taiwan Endocrine Society.
  • Keech, A. (2006). Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The FIELD study, a randomised controlled trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Keech, A., Best, J. (2006). Highlights from the FIELD trial: a landmark trial. Annual Scientific Sessions of the American Diabetes Association.
  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Keech, A. (2006). Individual and combined effects of fenofibrate and sulphonylureas on HDL cholesterol and outcomes. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Keech, A. (2006). Issues in clinical trial design and management: example of the role of PPAR-alpha agonists in prevention of CVD, satellite symposium. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Keech, A. (2006). Metabolic syndrome and diabetes. NHLBI National Cholesterol Education Program (USA).
  • Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Hiukka, A., Leinonen, E., Hilden, H., Perttunen-Nio, H., Keech, A., Taskinen, M. (2006). Reduction of large VLDL particles by fenofibrate is associated with reduction of small dense LDL in type 2 diabetes: Field Helsinki substudy. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Keech, A. (2006). Role of PPAR-alpha agonists in diabetic disease. Metabolic Syndrome Institute Meeting.
  • Keech, A. (2006). To manage diabetes: management in the early stages. Solvay Scientific Meeting.
  • Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
  • Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
  • Keech, A. (2005). Developing evidence-based practice in Diabetes care: FIELD, a Landmark Trial. American Diabetes Association 2005.
  • Keech, A. (2005). FIELD study: a large scale trial of fibrate therapy in diabetes. ASEAN Federation of Endocrine Societies.
  • Keech, A. (2005). The long-term efficacy and safety of Fenofibrate therapy to prevent cardiovascular events in 9795 people with type 2 diabetes mellitus: the main results of the FIELD study. American Heart Association Annual Scientific Sessions.
  • Keech, A. (2004). Effects of fenofibrate on lipid parameters in Type 2 Diabetes: a large-scale trial to prevent cardiovascular disease. 40th Annual Meeting of the EASD.
  • Keech, A. (2004). Rationale for a large-scale trial of fenofibrate to prevent cardiovascular disease in Type 2 Diabetes. Fournier Symposium; Taiwan Endocrinology & Diabetes Association Meeting.
  • Keech, A. (2004). Significant lipid changes with fenofibrate in Type 2 Diabetes in a large-scale trial to prevent cardiovascular disease. APSAVD Meeting.
  • Keech, A. (2003). Logistics of large scale studies in diabetes and vascular studies – FIELD & HPS. Australian Nurses Cardiovascular & Hypertension Association.
  • Keech, A. (2003). The Heart Protection Study: Results and clinical implications for treatment of patients in the Asia-Pacific and international lipid guidelines. International Atherosclerosis Society.
  • Keech, A. (2003). The link between Chronic Inflammation, Obesity and Endothelial Dysfunction. Cardiac Society of Australia & New Zealand.
  • Keech, A. (2002). An update on clinical trials in diabetes. Australian Diabetes Society.
  • Keech, A. (2002). Approaches to the patient with metabolic syndrome. ASEANZ 2002.
  • Keech, A. (2002). Challenges in the prevention of atherosclerosis in the Asia-Pacific region. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
  • Keech, A. (2002). Clinical Trials: drug or class effects? 14th ASEAN Congress of Cardiology.
  • Keech, A. (2002). Evidence-based clinical practice in diabetes. European Association of Diabetes Societies.
  • Keech, A. (2002). HDL cholesterol: a new therapeutic target for CHD prevention. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
  • Keech, A. (2002). New insights from the Heart Protection Study. Asian Congress of Cardiology. Asian Congress of Cardiology.
  • Keech, A. (2002). Principles of prospective meta-analysis. Clinical Trials Symposium.
  • Keech, A. (2002). Rationale, results and implications of the Heart Protection Study. Malaysian Medical Society Meeting.
  • Keech, A. (2002). Recent advances in clinical trials for treatment of atherosclerosis in diabetes. Australian Health & Medical Research Congress 2002.

Report

  • Keech, A. (2004). PBAC review of eligibility criteria for lipid lowering drugs.

2014

  • White, H., Tonkin, A., Simes, R., Stewart, R., Mann, K., Thompson, P., Colquhoun, D., West, M., Nestel, P., Sullivan, D., Keech, A., et al (2014). Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina. Journal of the American College of Cardiology, 63(4), 345-354. [More Information]

2013

  • Sullivan, T., Duque, G., Keech, A., Herrmann, M. (2013). An Old Friend in a New Light: The Role of Osteocalcin in Energy Metabolism. Cardiovascular Therapeutics (Online), 31(2), 65-75. [More Information]
  • Noonan, J., Jenkins, A., Ma, J., Keech, A., Wang, J., Lamoureux, E. (2013). An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, 62(12), 3968-3975. [More Information]
  • Ghosh, J., Martin, A., Keech, A., Chan, K., Gomes, S., Singarayar, S., McGuire, M. (2013). Balloon Warming Time Is the Strongest Predictor Of Late Pulmonary Vein Electrical Reconnection Following Balloon Cryoablation for Atrial Fibrillation. Heart Rhythm, 10(9), 1311-1317. [More Information]
  • White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, C., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
  • Ting, R., Keech, A. (2013). Fenofibrate and renal disease: Clinical effects in diabetes. Clinical Lipidology, 8(6), 669-680. [More Information]
  • Simo, R., Roy, S., Behar-Cohen, F., Keech, A., Mitchell, P., Wong, T. (2013). Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Current Medicinal Chemistry, 20(26), 3258-3266. [More Information]
  • Olver, I., Keech, A. (2013). Forming networks for research: proposal for an Australian clinical trials alliance. Medical Journal of Australia, 198(5), 254-255. [More Information]
  • Dignan, R., Keech, A., Gebski, V., Mann, K., Hughes, C. (2013). Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. International Journal of Cardiology, 168(6), 5378-5384. [More Information]
  • Chan, K., O'Connell, R., Sullivan, D., Hoffmann, L., Rajamani, K., Whiting, M., Donoghoe, M., Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng, M., Keech, A. (2013). Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia: clinical and experimental diabetes and metabolism, 56(4), 724-736. [More Information]
  • Hankey, G., Anderson, N., Ting, R., Veillard, A., Romo, M., Wosik, M., Sullivan, D., O'Connell, R., Hunt, D., Keech, A. (2013). Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. Journal of Neurology, Neurosurgery and Psychiatry, 84(3), 281-287. [More Information]
  • Chen, Y., Hu, Y., Lin, M., Jenkins, A., Keech, A., Mott, R., Lyons, T., Ma, J. (2013). Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes, 62(1), 261-272. [More Information]

2012

  • Donaghue, K., Keech, A., Craig, M., O'Connell, P. (2012). A 'cure' for diabetes and its complications. In Louise A. Baur, Stephen M. Twigg, Roger S.Magnusson (Eds.), A Modern Epidemic: Expert Perspectives on Obesity and Diabetes, (pp. 401-420). Sydney, Australia: Sydney University Press.
  • Ting, R., Keech, A., Drury, P., Donoghoe, M., Hedley, J., Jenkins, A., Davis, T., Lehto, S., Celermajer, D., Simes, R., Rajamani, K., et al (2012). Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment - The FIELD Study. Diabetes Care, 35(2), 218-225. [More Information]
  • Tonkin, A., Hunt, D., Voysey, M., Kesaniemi, Y., Hamer, A., Waites, J., Mahar, L., Mann, S., Glasziou, P., Forder, P., Simes, R., Keech, A. (2012). Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal, 163(3), 508-514. [More Information]
  • Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V. (2012). Effects of Fibrates in Kidney Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 60(20), 2061-2071. [More Information]
  • Best, J., Drury, P., Davis, T., Taskinen, M., Kesaniemi, Y., Scott, R., Pardy, C., Voysey, M., Keech, A. (2012). Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort. Diabetes Care, 35(5), 1165-1170. [More Information]
  • Emberson, J., Kearney, P., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., Collins, R., Simes, R., et al (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175 000 people in 27 randomised trials of statin therapy. PLoS One, 7(1), 1-10. [More Information]
  • Preiss, D., Tikkanen, M., Welsh, P., Ford, I., Lovato, L., Elam, M., laRosa, J., DeMicco, D., Colhoun, H., Goldenberg, I., Keech, A., et al (2012). Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis. JAMA, 308(8), 804-811. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Herrmann, M., Whiting, M., Veillard, A., Ehnholm, C., Sullivan, D., Keech, A. (2012). Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study. Clinical Chemistry and Laboratory Medicine, 50(12), 2213-2219. [More Information]
  • Fulcher, J., Keech, A. (2012). The case for more intensive use of statins. Therapeutic Advances in Chronic Diseases, 3(5), 201-210. [More Information]
  • Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, R., Barnes, E., Voysey, M., Gray, A., Collins, R., Baigent, C., et al (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. [More Information]
  • Ng, M., Yong, A., Ho, M., Shah, M., Chawantanpipat, C., O'Connell, R., Keech, A., Kritharides, L., Fearon, W. (2012). The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Circulation. Cardiovascular Interventions, 5(4), 515-522. [More Information]
  • Keech, A., Simes, R., Fulcher, J. (2012). The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 197(3), 130-131. [More Information]

2011

  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P., Neil, G., Haapamäki, H., Keech, A. (2011). Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 94(2), 284-290. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290. [More Information]
  • Drury, P., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., Fassett, R., Ansquer, J., Dixon, P., Davis, T., Pardy, C., Keech, A., et al (2011). Estimated Glomerular Filtration Rate and Albuminuria are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(1), 32-43. [More Information]
  • Scott, R., Donoghoe, M., Watts, G., O'Brien, R., Pardy, C., Taskinen, M., Davis, T., Colman, P., Manning, P., Fulcher, G., Keech, A. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), 102-1-102-8. [More Information]
  • Hayes, A., Clarke, P., Voysey, M., Keech, A. (2011). Simulation of Quality-Adjusted Survival in Chronic Diseases: An Application in Type 2 Diabetes. Medical Decision Making: an international journal, 31(4), 559-570. [More Information]

2010

  • Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One, 5(1), e8580-1-e8580-10. [More Information]
  • Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Mann, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia: clinical and experimental diabetes and metabolism, 53(9), 1846-1855. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290. [More Information]
  • Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., Keech, A., Simes, R., et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. [More Information]
  • Burgess, D., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T., Laakso, M., Kesaniemi, Y., Zhang, J., Sy, R., Keech, A., et al (2010). Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal, 31(1), 92-99. [More Information]
  • Chan, K., Chawantanpipat, C., Gattorna, T., Chantadansuwan, T., Kirby, A., Madden, A., Keech, A., Ng, M. (2010). The relationship between coronary stenosis severity and compression type coronary artery movement in acute myocardial infarction. American Heart Journal, 159(4), 584-592. [More Information]

2009

  • Keech, A., Horowitz, J. (2009). Cost-effectiveness Considerations of Cardiovascular Therapeutics. Heart, Lung and Circulation, 18(2), 118-122. [More Information]
  • Rajamani, K., Coleman, P., Li, L., Best, J., Voysey, M., D'Emden, M., Laakso, M., Baker, J., Keech, A., FIELD study investigators, F. (2009). Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet, 373(9677), 1780-1788. [More Information]
  • Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Boey (Tse), D., Taskinen, M., Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 32(3), 493-498. [More Information]
  • Soderberg, S., Colquhoun, D., Keech, A., Yallop, J., Barnes, E., Pollicino, C., Simes, R., Tonkin, A., Nestel, P. (2009). Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity, 33(1), 123-130. [More Information]
  • Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
  • Clarke, P., Hayes, A., Glasziou, P., Scott, R., Simes, R., Keech, A. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61-68. [More Information]

2008

  • Cook, D., Keech, A., Gebski, V., Pike, R., Wonders, S. (2008). Balancing the outcomes: reporting harms (adverse events). In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 132-142). Sydney: AMPCo.
  • Hayes, A., Clarke, P., Glasziou, P., Simes, R., Drury, P., Keech, A. (2008). Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care, 31(4), 795-797. [More Information]
  • Kearney, P., Blackwell, L., Collins, R., Keech, A., Simes, R., Peto, R., Armitage, J., Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet, 371, 117-125. [More Information]
  • Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - author's reply. The Lancet, 371, 722.
  • Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - Authors' reply. The Lancet, 371(9614), 722-722.
  • Keech, A., Mitchell, P. (2008). FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy. Review of Endocrinology.
  • Hiukka, A., Westerbacka, J., Leinonen, E., Watanabe, H., Wiklund, O., Hulten, L., Salonen, J., Tuomainen, T., Yki-Järvinen, H., Keech, A., et al (2008). Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. Journal of the American College of Cardiology, 52(25), 2190-2197. [More Information]
  • Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry (Washington, DC), 54(6), 1038-1045. [More Information]
  • Kearney, P., Keech, A., Simes, R., Collins, R. (2008). Statins and diabetes: authors' reply. The Lancet, 371(9626), 1752-1752.

2007

  • Scott, R., D'Emden, M., Best, J., Drury, P., Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D., Barter, P., Taskinen, M., Copt, S., Keech, A., et al (2007). Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate. Circulation, 116, II_838.
  • Keech, A., Gebski, V., Forder, P. (2007). Allocation concealment and blinding: when ignorance is bliss. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 54-64). Sydney: AMPCo.
  • Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
  • Keech, A., Gebski, V., Burgess, D. (2007). Baseline data in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 86-91). Sydney: AMPCo.
  • Marschner, C., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
  • Davis, W., Davis, T., Keech, A. (2007). Calculating cardiovascular risk in people with diabetes. Diabetes Management Journal, 18(March), 32-32.
  • Banks, E., Redman, S., Jorm, L., Armstrong, B., Bauman, A., Beard, J., Bowles, H., Butow, P., Cardona-Morrell, M., Clarke, J., Cowie, C., Cumming, R., Fragar, L., Keech, A., Kendig, H., Kricker, A., Morgan, G., Nutbeam, D., Quine, S., Salkeld, G., et al (2007). Cohort Profile the 45 and Up Study. International Journal of Epidemiology, September 2007, 1-6.
  • Keech, A., Gebski, V., Kirby, A. (2007). Determining the sample size in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 28-38). Sydney: AMPCo.
  • Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
  • Keech, A., Gebski, V., Vachan, B. (2007). Flow of participants in randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 72-78). Sydney: AMPCo.
  • Keech, A., Seale, J., Gebski, V. (2007). Generalising the results of trials to clinical practice. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 149-153). Sydney: AMPCo.
  • Keech, A., Gebski, V., Heritier, S. (2007). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 92-98). Sydney: AMPCo.
  • Keech, A., Gebski, V., Pike, R. (2007). Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: AMPCo.
  • Keech, A., Pike, R., Granger, R., Gebski, V. (2007). Interpreting the results of a clinical trial. Medical Journal of Australia, 186(9), 318-319. [More Information]
  • Keech, A., Gebski, V., Pike, R., Granger, R. (2007). Interpreting the results of a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 143-148). Sydney: AMPCo.
  • Keech, A., Ghersi, D., Gebski, V., Pike, R. (2007). Introducing the report of a randomised controlled trial: the title, abstract, scientific background and rationale. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 8-10). Sydney: AMPCo.
  • Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A., Taskinen, M. (2007). Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia: clinical and experimental diabetes and metabolism, 50(10), 2067-2075. [More Information]
  • O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Managing the resource demand of a large sample in clinical trials: can you succeed with fewer subjects? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 39-45). Sydney: AMPCo.
  • Keech, A., Gebski, V., Lord, S. (2007). Multiple analyses in clinical trials: sound science or data dredging? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 123-131). Sydney: AMPCo.
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. Medical Journal of Australia, 186(7), 368-370. [More Information]
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 154-161). Sydney: AMPCo.
  • Beller, E., Gebski, V., Keech, A. (2007). Randomisation in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 46-53). Sydney: AMPCo.
  • Gebski, V., Beller, E., Keech, A., Van Der Weyden, M. (2007). Randomised Controlled Trials: Elements of a Good Study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 7-22). Sydney: AMPCo.
  • Keech, A., Gebski, V., Beller, E., Van Der Weyden, M. (2007). Randomised controlled trials: elements of a good study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 1-7). Sydney: AMPCo.
  • Hague, W., Keech, A., Gebski, V., Pike, R. (2007). Recruitment to randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 78-85). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Selecting participants for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 11-15). Sydney: AMPCo.
  • Brighton, J., Gebski, V., Keech, A. (2007). Specifying intervention in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 16-20). Sydney: AMPCo.
  • Keech, A., Gebski, V., Marschner, C. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 21-26). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Statistical methods in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 65-71). Sydney: AMPCo.
  • Cook, D., Keech, A., Gebski, V. (2007). Subgroup analysis in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 105-113). Sydney: AMPCo.
  • Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.

2006

  • Keech, A. (2006). Challenges in undertaking primary prevention trials. 54th Annual Scientific Meeting of the Cardiac Society of Australian and New Zealand.
  • Keech, A., Simes, R. (2006). Clinical trial design & management: The role of PPAR-ALPHA agonists in prevention of CVD. Atherosclerosis Supplements, 7(3), 174-174.
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
  • Keech, A. (2006). Effects of long-term fenofibrate therapy in the FIELD study. Meeting of the Taiwan Endocrine Society.
  • Keech, A. (2006). Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The FIELD study, a randomised controlled trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment - Reply. The Lancet, 367(9509), 470-471.
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment-authors' reply [letter]. The Lancet, 367(9509), 470-471.
  • Keech, A., Best, J. (2006). Highlights from the FIELD trial: a landmark trial. Annual Scientific Sessions of the American Diabetes Association.
  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Keech, A. (2006). Individual and combined effects of fenofibrate and sulphonylureas on HDL cholesterol and outcomes. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Alexander, K., Newby, L., Bhapkar, M., White, H., Hochman, J., Pfisterer, M., Moliterno, D., Peterson, E., Van de Werf, F., Simes, R., Keech, A., et al (2006). International variation in invasive care of the elderly with acute coronary syndromes. European Heart Journal, 27(13), 1558-1564. [More Information]
  • Burgess, D., Kilborn, M., Keech, A. (2006). Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. European Heart Journal, 27(23), 2846-2857. [More Information]
  • Keech, A. (2006). Issues in clinical trial design and management: example of the role of PPAR-alpha agonists in prevention of CVD, satellite symposium. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Keech, A. (2006). Metabolic syndrome and diabetes. NHLBI National Cholesterol Education Program (USA).
  • Grieve, S., Ansquer, J., Keech, A. (2006). Micronized fenofibrate: A useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology, 2(6), 635-646.
  • Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Hiukka, A., Leinonen, E., Hilden, H., Perttunen-Nio, H., Keech, A., Taskinen, M. (2006). Reduction of large VLDL particles by fenofibrate is associated with reduction of small dense LDL in type 2 diabetes: Field Helsinki substudy. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Keech, A. (2006). Role of PPAR-alpha agonists in diabetic disease. Metabolic Syndrome Institute Meeting.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. Journal of the National Cancer Institute, 98(17), 1021-1022.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. Journal of the National Cancer Institute, 98(1), 26-38. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143.
  • Keech, A. (2006). To manage diabetes: management in the early stages. Solvay Scientific Meeting.

2005

  • Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding [reply]. Medical Journal of Australia, 183(3), 165-166.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding: when ignorance is bliss. Medical Journal of Australia, 182(2), 87-89. [More Information]
  • McAvoy, B., Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family Physician, 34(4), 297-298. [More Information]
  • Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
  • Briffa, T., Eckermann, S., Griffiths, A., Harris, P., Heath, M., Freedman, B., Donaldson, L., Briffa, N., Keech, A. (2005). Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Medical Journal of Australia, 183(9), 450-455. [More Information]
  • Keech, A. (2005). Developing evidence-based practice in Diabetes care: FIELD, a Landmark Trial. American Diabetes Association 2005.
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with chronic kidney disease and diabetes mellitus. Hypertension, 46(4), 900-901.
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology, 16(12), 3748-3754. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278. [More Information]
  • Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
  • Keech, A. (2005). FIELD study: a large scale trial of fibrate therapy in diabetes. ASEAN Federation of Endocrine Societies.
  • Lundman, P., Keech, A., Griffiths, K., Pillai, A., Celermajer, D. (2005). New carotid plaque formation is very common in adult patients with Type 2 diabetes mellitus. Diabetic Medicine, 22(3), 355-356. [More Information]
  • Keech, A. (2005). The long-term efficacy and safety of Fenofibrate therapy to prevent cardiovascular events in 9795 people with type 2 diabetes mellitus: the main results of the FIELD study. American Heart Association Annual Scientific Sessions.
  • Keech, A., Grieve, S., Patel, A., Griffiths, K., Skilton, M., Watts, G., Marwick, T., Groshens, M., Celermajer, D. (2005). Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. Diabetic Medicine, 22(11), 1558-1565. [More Information]

2004

  • Keech, A., Wonders, S., Cook, D., Gebski, V. (2004). Balancing the outcomes: reporting adverse events. Medical Journal of Australia, 181(4), 215-218.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. The Lancet, 363(9411), 757-767.
  • Keech, A. (2004). Effects of fenofibrate on lipid parameters in Type 2 Diabetes: a large-scale trial to prevent cardiovascular disease. 40th Annual Meeting of the EASD.
  • Colquhoun, D., Keech, A., Hunt, D., Marschner, C., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
  • Seale, J., Gebski, V., Keech, A. (2004). Generalising the results of trials to clinical practice. Medical Journal of Australia, 181(10), 558-560.
  • O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.
  • Lord, S., Gebski, V., Keech, A. (2004). Multiple Analyses In Clinical Trials: Sound Science Or Data Dredging? Medical Journal of Australia, 181(8), 452-454.
  • Keech, A. (2004). PBAC review of eligibility criteria for lipid lowering drugs.
  • Keech, A. (2004). Rationale for a large-scale trial of fenofibrate to prevent cardiovascular disease in Type 2 Diabetes. Fournier Symposium; Taiwan Endocrinology & Diabetes Association Meeting.
  • Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
  • Keech, A. (2004). Significant lipid changes with fenofibrate in Type 2 Diabetes in a large-scale trial to prevent cardiovascular disease. APSAVD Meeting.
  • Cook, D., Gebski, V., Keech, A. (2004). Subgroup analysis in clinical trials. Medical Journal of Australia, 180(6), 289-291.
  • Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
  • Barter, P., Best, J., Colman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Glasziou, P., Hunt, D., Keech, A., Forder, P., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11.

2003

  • Sniderman, A., Furberg, C., Keech, A., Roeters van Lennep, J., Frohlich, J., Jungner, I., Walldius, G. (2003). Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. The Lancet, 361(9359), 777-780.
  • Burgess, D., Gebski, V., Keech, A. (2003). Baseline data in clinical trials. Medical Journal of Australia, 11, 105-107.
  • Pike, R., Keech, A., Simes, R. (2003). Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Medical Journal of Australia, 178(7), 316-317.
  • Kirby, A., Gebski, V., Keech, A. (2003). Determining the sample size in a clinical trial [in reply]. Medical Journal of Australia, 178(7), 358-358.
  • Vachan, B., Gebski, V., Keech, A. (2003). Flow of participants in randomised studies. Medical Journal of Australia, 178, 347-349.
  • Heritier, S., Gebski, V., Keech, A. (2003). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Medical Journal of Australia, 11, 438-440.
  • Keech, A. (2003). Logistics of large scale studies in diabetes and vascular studies – FIELD & HPS. Australian Nurses Cardiovascular & Hypertension Association.
  • Keech, A., Gebski, V. (2003). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects. Medical Journal of Australia, 178(7), 356-357.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., et al (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet, 361(9374), 2005-2016.
  • Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., McAvoy, B., Neale, M., Pollock, C., et al (2003). Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus, (21 July 2003), 1-14.
  • Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
  • Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721.
  • Gebski, V., Keech, A. (2003). Statistical methods in clinical trials. Medical Journal of Australia, 11, 182-184.
  • Keech, A. (2003). The Heart Protection Study: Results and clinical implications for treatment of patients in the Asia-Pacific and international lipid guidelines. International Atherosclerosis Society.
  • Keech, A. (2003). The link between Chronic Inflammation, Obesity and Endothelial Dysfunction. Cardiac Society of Australia & New Zealand.

2002

  • Keech, A. (2002). An update on clinical trials in diabetes. Australian Diabetes Society.
  • Keech, A. (2002). Approaches to the patient with metabolic syndrome. ASEANZ 2002.
  • Keech, A. (2002). Challenges in the prevention of atherosclerosis in the Asia-Pacific region. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
  • Keech, A. (2002). Clinical Trials: drug or class effects? 14th ASEAN Congress of Cardiology.
  • Kilian, J., Keech, A., Adams, M., Celermajer, D. (2002). Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. Coronary Artery Disease, 13(3), 155-159.
  • Sacks, F., Tonkin, A., Craven, T., Pfeffer, M., Shepherd, J., Keech, A., Furberg, C., Braunwald, E. (2002). Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105(12), 1424-1428.
  • Kirby, A., Gebski, V., Keech, A. (2002). Determining the sample size in a clinical trial. Medical Journal of Australia, , 256-257.
  • Neal, B., MacMahon, S., Ohkubo, T., Tonkin, A., Wilcken, D., Keech, A. (2002). Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. European Heart Journal, 23(19), 1509-1515.
  • Simes, R., Furberg, C., Braunwald, E., Davis, B., Ford, I., Tonkin, A., Shepherd, J., Keech, A. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. European Heart Journal, 23(3), 207-215.
  • Keech, A., Neal, B., MacMahon, S., Ohkubo, T., Brnabic, A., Tonkin, A. (2002). Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. Journal Of The Renin-Angiotensin-Aldosterone System, 3(4), 270-276.
  • Keech, A. (2002). Evidence-based clinical practice in diabetes. European Association of Diabetes Societies.
  • Keech, A. (2002). HDL cholesterol: a new therapeutic target for CHD prevention. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
  • Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387.
  • Keech, A., Gebski, V. (2002). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Medical Journal of Australia, 177(8), 437-439.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360, 23-33.
  • Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360(9326, 6 July 2002), 7-22.
  • Keech, A. (2002). New insights from the Heart Protection Study. Asian Congress of Cardiology. Asian Congress of Cardiology.
  • Keech, A. (2002). Principles of prospective meta-analysis. Clinical Trials Symposium.
  • Beller, E., Gebski, V., Keech, A. (2002). Randomisation in clinical trials. Medical Journal of Australia, 177(10), 565-567.
  • Simes, R., Keech, A., et, A. (2002). Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 105(3), 316-321.
  • Keech, A. (2002). Rationale, results and implications of the Heart Protection Study. Malaysian Medical Society Meeting.
  • Keech, A. (2002). Recent advances in clinical trials for treatment of atherosclerosis in diabetes. Australian Health & Medical Research Congress 2002.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • Richie, G., Keech, A., Yamamoto,, A., Nakamura, H., Hosoda,, S., Nobuyoshi,, M., Matsuzaki, M., Tan, C., Mabuchi, H., Horibe, H., et al (2002). Risk factors for coronary heart disease in the Japanese - Comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Journal of Atherosclerosis and Thrombosis, 9(4), 191-199.
  • Pfeffer, M., Keech, A., Sacks, F., Cobbe, S., Tonkin, A., Byington, R., Davis, B., Friedman, C., Braunwald, E. (2002). Safety and tolerability of pravastatin in long-term clinical trials. Circulation, 105(20), 2341-2346.
  • Brighton, J., Gebski, V., Keech, A. (2002). Specifying interventions in a clinical trial. Medical Journal of Australia, , 281-282.
  • Gebski, V., Marschner, C., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492.

2001

  • Ritchie, G., Keech, A. (2001). Asia-Pacific collaboration on coronary heart disease risk factor intervention: study desing and methods. Heart, Lung and Circulation, 10, 24-29.
  • Hughes, C., Keech, A., Cox,, N. (2001). Myocardial infarction due to saphenous vein graft compression by an extracardiac mass. Heart, Lung and Circulation, 10, 35-37.
  • Gebski, V., Beller, E., Keech, A. (2001). Randomized controlled trails: elements of a good study. Medical Journal of Australia, 175, 272-274.
  • Ghersi, D., Gebski, V., Keech, A. (2001). Scientific background and rationale for a randomised controlled trial. Medical Journal of Australia, 175(7), 386-386.
  • Keech, A., Gebski, V. (2001). Selecting participants for clinical trials. Medical Journal of Australia, 175(9), 490-491.

2000

  • Miller, O., Tang, S., Keech, A., Pigott, N., Beller, E., Celermajer, D. (2000). Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. The Lancet, 356(9240), 1464-1469.

To update your profile click here. For support on your academic profile contact .